The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review
Recurrence of FSGS occurs in 30–40% of allografts. Therapies for recurrence are not well established. We retrieved all published reports depicting kidney transplant recipients with focal segmental glomerulosclerosis (FSGS) recurrence, treated with rituximab, to determine factors associated with trea...
Main Authors: | Carlos E. Araya, Vikas R. Dharnidharka |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Journal of Transplantation |
Online Access: | http://dx.doi.org/10.1155/2011/374213 |
Similar Items
-
Treatment of Recurrent Focal Segmental Glomerulosclerosis
in Pediatric Kidney Transplant Recipients: Effect of Rituximab
by: Christine Sethna, et al.
Published: (2011-01-01) -
Intravenous Rituximab in Severe Refractory Primary Focal Segmental Glomerulosclerosis
by: Wee Leng Gan, et al.
Published: (2018-10-01) -
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
by: Panupong Hansrivijit, et al.
Published: (2020-04-01) -
RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AFTER KIDNEY TRANSPLANTATION
by: Nuno Moreira Fonseca
Published: (2019) -
Focal Segmental Glomerulosclerosis and Recurrence in Living Donor Recipients
by: Mang J, et al.
Published: (2021-07-01)